Caxton Associates LP Takes Position in Teva Pharmaceutical Industries Limited (TEVA)

Caxton Associates LP acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 12,200 shares of the company’s stock, valued at approximately $391,000.

Other hedge funds also recently added to or reduced their stakes in the company. Cribstone Capital Management LLC boosted its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the last quarter. Sterling Investment Advisors Ltd. boosted its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the last quarter. Financial Architects Inc boosted its stake in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares during the last quarter. Finally, Botty Investors LLC bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth $160,000. 56.26% of the stock is currently owned by institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 0.8886% during midday trading on Tuesday, hitting $32.6572. 1,372,465 shares of the company’s stock traded hands. The stock has a market cap of $33.18 billion, a P/E ratio of 418.6820 and a beta of 0.49. Teva Pharmaceutical Industries Limited has a 52 week low of $27.60 and a 52 week high of $56.44. The company has a 50 day moving average of $30.17 and a 200 day moving average of $33.07.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.06. The firm had revenue of $5.63 billion for the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. During the same period in the previous year, the company earned $1.20 earnings per share. Teva Pharmaceutical Industries Limited’s revenue was up 17.0% compared to the same quarter last year. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.78 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, June 22nd. Investors of record on Monday, June 5th were given a $0.34 dividend. The ex-dividend date of this dividend was Thursday, June 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 4.13%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is 5,802.90%.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Mideast Time and is owned by of Mideast Time. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.mideasttime.com/caxton-associates-lp-takes-position-in-teva-pharmaceutical-industries-limited-teva/1814287.html.

A number of research firms have weighed in on TEVA. Jefferies Group LLC reissued a “hold” rating and set a $33.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Friday. Cantor Fitzgerald began coverage on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, June 15th. They issued a “neutral” rating and a $31.00 target price on the stock. Mizuho raised shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and lifted their target price for the company from $25.00 to $30.00 in a report on Thursday, June 15th. Royal Bank Of Canada set a $38.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Friday, June 16th. Finally, Vetr cut shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price on the stock. in a report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $43.56.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.